Telehealth providers in Illinois
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
Telehealth prescribing is allowed in Illinois. What Illinois requires of telehealth prescribers and pharmacies, plus listings with their verification status.
Illinois at a glance
- Pharmacy regulator
- Illinois State Board of Pharmacy (Illinois Department of Financial and Professional Regulation)
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async unclear
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Telehealth providers serving Illinois
Prescription peptides through an online assessment and a licensed provider review, shipped from a licensed U.S. compounding pharmacy.
Telehealth provider · 17 products · partner lists from $172 a month · Says it serves Illinois (not yet confirmed)
- Prescription only, no research-use-only sales
- Public cancellation and refund policy
We may earn a commission from these links.
Telehealth prescribing rules in Illinois
The Telehealth Act (225 ILCS 150) lets a health care professional practice telehealth services to the extent of the scope of practice in the professional's licensing act, consistent with the in-person standard of care (section 15), and requires a professional treating a patient located in Illinois to be licensed or authorized to practice in Illinois (section 10). Section 49.5 of the Medical Practice Act (225 ILCS 60/49.5) separately requires a physician engaged in telemedicine with Illinois patients to hold an Illinois license or permit. Section 5 of the Telehealth Act defines telehealth services as the evaluation, diagnosis, or interpretation of electronically transmitted patient-specific data that generates interaction or treatment recommendations, and says they include care delivered by an interactive telecommunications system, an asynchronous store and forward system (transmission that does not require real-time interaction), remote patient monitoring, e-visits, or virtual check-ins. E-visits and virtual check-ins are defined as communications with an established patient; the store and forward definition has no such limit. The Act also says it does not authorize care in a setting or manner not otherwise authorized by Illinois law. No Illinois statute sets a real-time video requirement for non-controlled prescriptions, and none addresses questionnaire-only prescribing. This record leaves asynchronous prescribing unknown because the law is silent on the point: asynchronous store and forward care is a recognized telehealth modality, but neither the Telehealth Act nor the Medical Practice Act says how a practitioner-patient relationship is formed or whether a first prescription may follow an asynchronous evaluation, and we found no Illinois Department of Financial and Professional Regulation guidance on it. [2] [5]
Compounded GLP-1 access in Illinois
Illinois patients using telehealth GLP-1 programs should confirm the prescriber holds an Illinois license or permit and that the dispensing pharmacy holds an IDFPR nonresident pharmacy license. IDFPR has not issued its own GLP-1 rule, but it relays federal positions to licensees: its Pharmacy page posts FDA's July 2024 letter on adverse events with compounded semaglutide and tirzepatide, and its Spring 2025 compliance newsletter restated FDA's timelines that ended 503A enforcement discretion for compounded tirzepatide and set April 22, 2025 for semaglutide. [1] [2] [3] [5] [7] [9]
Research use only sellers in Illinois
Only IDFPR-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Illinois patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. The Illinois Food, Drug and Cosmetic Act, 410 ILCS 620/17, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has been approved under section 505 of the federal act, and 68 Ill. Adm. Code 1330.30(j) makes dispensing a drug that is not FDA approved, not in the USP-NF, and not on the FDA bulks list unprofessional conduct for a licensee. [3] [4] [6] [10]
How to check a telehealth provider in Illinois
- Confirm the prescriber is licensed or registered to treat patients located in Illinois; the telehealth rules above explain what Illinois requires. [2] [5]
- Ask which pharmacy will fill the prescription and check it in the Illinois State Board of Pharmacy (Illinois Department of Financial and Professional Regulation) license lookup. [1] [3] [4] [8]
- Get the full price in writing first: consult fees, membership fees, and the medication itself.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Illinois. [3] [4] [6] [10]
Common questions in Illinois
Can I get a GLP-1 prescription through telehealth in Illinois?
Yes, from a provider licensed or authorized to practice in Illinois. The Illinois Telehealth Act lets licensed professionals practice by telehealth within their scope of practice, held to the same standard of care as in-person visits. Illinois law does not settle whether a first prescription may follow an asynchronous evaluation with no live visit. It counts asynchronous store and forward care as telehealth, but it does not say how the practitioner-patient relationship is formed. [5]
What does an out-of-state pharmacy need to ship compounded peptides to Illinois?
A nonresident pharmacy license from the Illinois Department of Financial and Professional Regulation under 225 ILCS 85/16a, which covers pharmacies that ship or deliver prescription drugs into Illinois by any means, including online. Check the IDFPR license lookup before ordering. [1] [3]
Sources
- [1]Illinois Department of Financial and Professional Regulation: Pharmacy (State Board of Pharmacy)
- [2]Illinois Medical Practice Act, 225 ILCS 60/49.5, Telemedicine
- [3]Illinois Pharmacy Practice Act, 225 ILCS 85/16a, Nonresident pharmacies
- [4]68 Illinois Administrative Code Part 1330, Pharmacy Practice Act rules (including sections 1330.30 and 1330.640)
- [5]Illinois Telehealth Act, 225 ILCS 150, sections 5, 10, and 15 (Illinois General Assembly)
- [6]Illinois Food, Drug and Cosmetic Act, 410 ILCS 620/17, New drugs (Illinois General Assembly)
- [7]IDFPR Compliance Capsule, Spring 2025 (semaglutide and tirzepatide compounding updates)
- [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [10]21 U.S.C. 331, Prohibited acts